Did JNJ and ABBV beat revenue expectations in Q1 2026?

Yes, both companies exceeded revenue expectations in Q1 2026.

What were JNJ's main growth drivers in Q1?

JNJ leveraged its diversified pharma and MedTech segments, with notable contributions from TREMFYA and cardiovascular drugs.

What was AbbVie's main growth driver in Q1?

AbbVie relied almost entirely on immunology, particularly Skyrizi.

What challenges do JNJ and ABBV face?

Both companies face headwinds from biosimilar competition.

Johnson & Johnson and AbbVie Beat Q1 2026 Estimates, Raise Guidance

Q: Did JNJ and ABBV raise their annual guidance after the results?

Yes, both companies raised their full-year 2026 guidance.

Johnson & Johnson (JNJ) and AbbVie (ABBV) both reported Q1 2026 results that beat revenue expectations, leading to raised full-year guidance. JNJ leveraged its diversified pharma and MedTech portfolio, while AbbVie relied heavily on immunology. Both face biosimilar headwinds but chose different growth paths.

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) reported first-quarter 2026 results that exceeded revenue expectations, prompting both companies to raise their full-year guidance. The strong performance reflects two distinct growth strategies amid biosimilar competition.

Key Financial Results

Company	Revenue	Net Income	EPS
JNJ	Beat expectations	Not disclosed	Not disclosed
ABBV	Beat expectations	Not disclosed	Not disclosed

Note: Specific figures were not provided in the source.

Highlights from the Reports

JNJ relied on its diversified pharmaceutical and MedTech engines, with TREMFYA and cardiovascular drugs driving growth. AbbVie leaned almost entirely on immunology, particularly Skyrizi.

Guidance

Both companies raised their full-year 2026 guidance, indicating management confidence in sustained performance.

Stock Impact

The earnings beat and raised guidance are expected to support JNJ and ABBV shares in the near term, though biosimilar headwinds remain a risk.

What This Means for Investors

The strong results demonstrate both companies' ability to grow despite competitive pressures. JNJ offers diversification, while AbbVie focuses on its immunology strength. Investors should monitor biosimilar developments and their impact on future revenue.